A5016401289- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
- Breast Cancer Treatment Studies
- Cancer Mechanisms and Therapy
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
- Chemotherapy-related skin toxicity
- Genetic Associations and Epidemiology
- Peptidase Inhibition and Analysis
- Astronomical Observations and Instrumentation
- Ubiquitin and proteasome pathways
- Endometriosis Research and Treatment
- Computational Drug Discovery Methods
- Colorectal Cancer Treatments and Studies
- Engineering and Information Technology
- Esophageal Cancer Research and Treatment
- Glioma Diagnosis and Treatment
- Cancer Risks and Factors
- Cancer-related cognitive impairment studies
Hospital Clínico Universitario Lozano Blesa
2014-2024
GEICAM – Spanish Breast Cancer Group
2020-2024
Instituto Tecnológico de Costa Rica
2024
University of Pennsylvania
2017
Icahn School of Medicine at Mount Sinai
2017
Madras Medical Mission
2017
Stanford University
2017
University of California, San Francisco
2017
Indiana University – Purdue University Indianapolis
2017
Cedars-Sinai Medical Center
2017
Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that chemotherapy in a phase III trial.PEARL multicentre, randomised study which patients aromatase inhibitor (AI)-resistant MBC were included two consecutive cohorts. In cohort 1, 1 : to palbociclib exemestane or capecitabine. On discovering new evidence about...
Abstract Purpose: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and discover therapeutic targets reverse this resistance. Non-luminal subtype high levels of CCNE1 are candidate biomarkers in setting, but further validation needed. Experimental Design: We performed mRNA gene expression profiling correlation with progression-free survival (PFS) on 455 tumor...
Abstract Background The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy patients hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. Methods Postmenopausal women untreated stage I–III HR+/HER2-negative were randomized (1:1:1) to receive 3 weeks letrozole (LTZ) 2.5 mg/day, mVNB 50 mg days/week, the combination. primary objective was evaluate, within PAM50 Luminal A/B disease, if anti-proliferative...
The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival postmenopausal patients with metastatic breast cancer resistant aromatase inhibitors, but better tolerated. This analysis compared patient-reported outcomes.The quality of life (QoL) population comprised 537 patients, 268 randomised palbociclib/ET (exemestane or fulvestrant) and 269 capecitabine. Patients completed the European Organisation...
An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) patients. Here, we report final overall (OS) analysis.Postmenopausal patients (N = 601) were randomized 1:1 to or ET (exemestane, Cohort 1; fulvestrant, 2). OS was analysed 2, wild-type...
Understanding the factors affecting semen quality is important for optimizing male reproductive efficiency. The present study aimed to evaluate seminal associated with breed, age, season, and sperm counting chamber in boar ejaculates. A total of 22 sexually mature healthy boars from maternal sire commercial breeds were utilized as donors, an average age (mean ± standard deviation) 21.0 7.2 months. Boars housed individually well-ventilated pens fed a breeder mix. Semen samples collected each...
Genome-wide association studies (GWAS) have identified 3 genomic regions, at 15q24-25.1, 5p15.33, and 6p21.33, which associate with the risk of lung cancer. Large meta-analyses GWA data failed to find additional associations genome-wide significance. In this study, we sought confirm 7 variants suggestive cancer (P < 10(-5)) in a recently published meta-analysis. dataset 1,447 cases 36,256 controls Iceland, correlated on 15q15.2 (rs504417, rs11853991, rs748404) showed significant cancer,...
Abstract Background: PAL is approved for use in combination with ET HR-positive, HER2-negative MBC pts first and later lines. However, the relative value of plus versus (vs) chemotherapy (CT) pretreated not established yet. PEARL a multinational, open label, controlled, randomized phase 3 trial comparing efficacy safety (exemestane [EXE] or fulvestrant [FUL]) vs CAPE postmenopausal women HR-positive/HER2-negative whose disease progressed on AIs. Methods: The study had two successive cohorts....
Aims and background The purpose of the study was to test immunological clinical effects infusions dendritic cells pulsed with autologous tumor lysate in patients advanced cancer. Patients methods Peripheral blood mononuclear from 15 metastatic cancer (melanoma 10, lung 2, renal cell carcinoma 1, sarcoma breast 1) were harvested by leukapheresis after mobilization GM-CSF (5 μg/kg/day s.c. for 4 days). Mononuclear separated cultured (1000 U/ml) interleukin-4 7 days. Phenotype assessed 2-color...
Alzheimer's disease (AD) is a progressive neurodegenerative that affects over 55 million people worldwide. Individuals with AD are often prescribed multiple medications to manage comorbidities, many of which metabolized by enzymes from the cytochrome P450 (CYP). CYP2C9 expressed gene. The highly polymorphic gene grouped into phenotypes such as poor, intermediate, normal, and ultra-rapid metabolizers influence pharmacokinetics (PK) drugs their metabolites. Among humans, one most essential for...
Abstract Background: Endocrine therapy (ET) and treatment directed against molecular targets (CDK 4/6, PI3K, mTOR) constitute the basis of initial treatments for patients with advanced luminal breast cancer. Most these are oral have been developed at a fixed dose, without weight adjusted dosing. There is little evidence on influence that patients’ might clinical outcomes drugs in context randomized trial. The present study analyzes potential impact treated two cohorts PEARL trial...
1023 Background: Cytoplasmic cyclin E protein expression, serving as a surrogate for the low molecular weight isoform (LMW-E), is biomarker associated with aggressive breast cancer and predicts resistance to aromatase inhibitors in luminal cancer. We investigated prognostic predictive value of cytoplasmic nuclear isoforms HR+/HER2- metastatic (MBC) patients receiving palbociclib CDK4/6 inhibitor endocrine therapy (PALBO+ET) versus capecitabine (CAPE) GEICAM/2013-02 PEARL trial (NCT02028507)....
Abstract Background: Endocrine therapy (ET) is the cornerstone treatment for HR–positive, HER2-negative breast cancer (BC) patients. AIs have become of choice in postmenopausal The high response rates with ET these patients are partially undermined by resistance developed most them over time. On early disease recurrence/progression to AIs, options include other AI, estrogen-receptor antagonists or chemotherapy (being capecitabine one best options). Preclinical data suggest that ER+/HER2- BC...
1014 Background: The randomized PEARL trial found no superiority of palbociclib plus endocrine therapy over capecitabine in patients (pts) with metastatic HR-positive, HER2-negative breast cancer resistant to prior aromatase inhibitors (Martin M, Ann Oncol 2020). Gene expression analysis showed high CCNE1 mRNA ( CCNE1) conferring relative resistance the PALOMA-3 (Turner N, JCO 2019), but further validation is needed. Cyclin E1 protein (cyclin E1) this context has not been studied trials. We...
10662 Background: T and M is a very active chemotherapy regimen for breast cancer. has been shown to be as effective doxorubicin at same doses while reducing the cardiotoxicity causing less myelosuppression. This study was designed evaluate clinical pathological response rate (RR) toxicity after induction in patient with Methods: Patients histological confirmation of cancer (stage II-III inflammatory), age > 18 years, left ventricular eject fraction 45% adequate bone marrow, renal hepatic...